nice tirzepatide obesity vs. Semaglutide for Patients with Obesity: A Head-to-Head Trial https://jwat.ch/3ZijGUc New Breakthrough Obesity Drug

If there's insulin resistance, if there are, uh, metabolic comorbidities, like there's already pre-diabetes type two diabetes, fatty liver disease, there's elevated cardiovascular risk that [00:41:00] is not improving despite trying everything, doing everything right, then that's when GLP ones are considered

Doktori kau da ljudi mogu imati stanje koje se zove odloeno pranjenje eluca, a da to ne znaju

Thyroid C-cell tumors: Semaglutide has a boxed warning for the risk of thyroid C-cell tumors

This effect likely relates to delayed gastric emptying, as high-fat foods naturally slow digestion further, potentially causing discomfort or early satiety

February 6, 2026: FDA press release FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs signals escalating enforcement posture

Pregnancy and Lactation: Safe for use, but always consult with healthcare professionalsthe benefits must outweigh the inherent risks